CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 12 enrolled
Drug / intervention
Doripenem +1 moredrug
Likely dose
Doripenem 500 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01401010
NCT01401010Phase 4Completed
CompareCT.gov

Pharmacokinetic/Pharmacodynamic Study of Doripenem in Febrile Neutropenic Patients With Possible Bacterial Infection

Gary E. Stein, Pharm.D.·interventional·Posted Jul 25, 2011·Updated Oct 14, 2015

In Brief

A Phase 4 clinical trial evaluating Doripenem and doripenem for Febrile Neutropenia. Completed, enrolled 12 participants across 1 site.

Detailed Summary

Primary: To determine the serum pharmacokinetics (PK) of doripenem in febrile neutropenic patients. Secondary: Monte Carlo Simulations Tested Against Various Gram-negative Isolates and Reported as Probability of Target Attainment (40% Time (fT)\> minimum inhibitory concentration (MIC))

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFebrile Neutropenia
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJul 25, 2011
Enrollment StartAug 1, 2010
Primary CompletionFeb 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 14.9 years ago

Interventions

Doripenemdrug

500 mg every 8 hours

doripenemdrug

1000 mg every 8 hours